Management ChangeJul 31, 2026, 08:34 AM
Vistagen Appoints Douglas J. Williamson, MD, to Board of Directors
AI Summary
Vistagen Therapeutics, Inc. announced the appointment of Douglas J. Williamson, MD, to its Board of Directors. Dr. Williamson brings significant experience in neuroscience drug development, having guided therapies from early development through regulatory approval and commercialization at companies like QurAlis, Acadia Pharmaceuticals, H. Lundbeck, and Eli Lilly. His expertise is expected to be invaluable as Vistagen advances its neuroscience pipeline and explores corporate growth opportunities.
Key Highlights
- Vistagen appointed Douglas J. Williamson, MD, to its Board of Directors.
- Dr. Williamson brings extensive experience in neuroscience drug development from early clinical research to commercialization.
- He is currently a CNS Drug Development Consultant and founder of Destiny Biopharm Consulting.
- Previously, he served as Chief Medical Officer of QurAlis Corporation and EVP, Head of R&D at Acadia Pharmaceuticals Inc.
- Dr. Williamson held senior leadership roles at H. Lundbeck A/S and contributed to therapies at Eli Lilly and Company.
- He previously served on the Board of Bright Minds Biosciences.
Price Impact
More from VTGN